Universal chimeric antigen receptor mucin 1 T-cell therapy - Cellectis
Alternative Names: MUC1 CAR T cells - Cellectis; UCARTMUC1; UCARTMUC1 - CellectisLatest Information Update: 05 Sep 2024
At a glance
- Originator Cellectis
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 03 Sep 2024 Pharmacodynamics data from preclinical studies in Solid tumours released by Cellectis
- 17 Apr 2023 Pharmacodynamics data from preclinical studies in Solid tumours presented at the Annual Meeting of American Association for Cancer Research (AACR-2023)
- 14 Jun 2021 Preclinical trials in Solid tumours in France (unspecified route) prior to June 2021